Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie for å evaluere PRO-240 oftalmisk løsning sammenlignet med Optive®

9. november 2026 oppdatert av: Laboratorios Sophia S.A de C.V.

Fase I klinisk studie for å evaluere sikkerheten og toleransen til PRO-240 oftalmisk løsning sammenlignet med Optive® på øyeoverflaten til oftalmologisk og klinisk friske frivillige

This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The variables to be evaluated include:

Primary (safety):

- Incidence of unexpected advere events (AE's)

Secondary:

  • Changes in the ocular comfort index (OCI) score
  • Changes in intraocular pressure (IOP)
  • Changes in Best Corrected Visual Acuity (BCVA)
  • Adherence to treatment
  • Changes in tear film breakup time
  • Changes in fluorescein staining
  • Changes in lissamine green staining

Studietype

Intervensjonell

Registrering (Antatt)

32

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Having the ability to voluntarily give their signed informed consent.
  • Ophthalmologically and clinically healthy subjects.
  • Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.
  • Age ≥18 years.
  • Male or female gender.
  • Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.
  • Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.
  • Corneal staining ≤ grade I on the Oxford Scale.
  • Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.

Exclusion Criteria:

  • History of hypersensitivity to any of the components of the drugs under investigation.
  • Use of ophthalmic medications from any pharmacological group.
  • Use of medications by any other route of administration.
  • Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or antibiotics by any route of administration in the last 30 days.
  • History of eye surgery in the last 6 months.
  • Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.
  • In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
  • Having participated in any clinical research study 30 days prior to inclusion in this study.
  • Having previously participated in this same study.
  • History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.
  • Diagnosis of glaucoma or ocular hypertension.
  • Known diagnosis of liver or heart disease.
  • Presenting active inflammatory or infectious disease at the time of entry into the study.
  • Presenting unresolved lesions or traumas at the time of entry into the study.
  • Having been subjected to non-ophthalmological surgical procedures in the last 3 months.
  • Being or having an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.
  • Active smoking (specified as the consumption of cigarettes regardless of the amount and frequency, 4 weeks prior to study inclusion and during the intervention period of this study).
  • Active alcoholism (specified as the consumption of alcoholic beverages, regardless of the amount and frequency, 72 hours prior to study inclusion and during the intervention period of this study).

Elimination Criteria:

  • Withdrawal of their consent to participate in the study (informed consent form).
  • Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
  • Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
  • Non-tolerability or hypersensitivity to any of the drugs under investigation.
  • Adherence < 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PRO-240
  • Propylene glycol 0.3% - Polyethylene glycol 400 0.5% - Glycerin 0.2%. Ophthalmic solution.
  • Dosage: 1 drop QID [4] (four times per day) for 7 days in both eyes.
  • Route of administration: Ophthalmic

-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.

Aktiv komparator: Optive®
  • Carboxymethylcellulose 0.5%; Glycerin 0.9%. Ophthalmic solution.
  • Dosage: 1 drop QID [4] (four times per day) for 7 days in both eyes.
  • Route of administration: Ophthalmic

- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of unexpected adverse events related to the interventions
Tidsramme: Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)

Any unfavorable medical condition affecting the subject after the administration of the investigation product, related to such intervention.

Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in the Ocular Comfort Index score
Tidsramme: Days: 0 (Basal Visit), and 8 (Final Visit)

Changes in the Ocular Comfort Index (OCI) score in between interventions, the subjects will be questioned regarding this symptoms' incidence. The OCI contains 8 items (one positive and eight negative) that focus on discomfort associated with ocular surface disorders. Each of these questions has two parts, which separately inquire about the frequency and severity of symptoms.

The OCI score will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.

Days: 0 (Basal Visit), and 8 (Final Visit)
Adherence to treatment (adherence) Adherence to treatment (adherence)
Tidsramme: Days: 8 (Final Visit)

Adherence will be evaluated through the treatment record in the subject's diary.

Days: 8 (Final Visit)
Changes in Best Corrected Visual Acuity (BCVA)
Tidsramme: Days: 0 (Basal Visit) and 8 (Final Visit)

The BCVA will be evaluated through Snellen chart.

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in tear film breakup time
Tidsramme: Days: 0 (Basal Visit) and 8 (Final Visit)

The most common method for assessing stability is with fluorescein. The precorneal layer colored with fluorescein will change to less fluorescent or non-fluorescent regions. The time from the last blink to the appearance of these regions is the tear film breakup time.

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in intraocular pressure (IOP)
Tidsramme: Days: 0 (Basal Visit) and 8 (Final Visit)

Previous instillation of topical anesthetic, the IOP will be measured through a Goldmann tonometer during visits

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in the integrity of the ocular surface (fluorescein staining)
Tidsramme: Days: 0 (Basal Visit) and 8 (Final Visit)

Changes in the integrity of the ocular surface using fluorescein staining and evaluated through the Oxford scale. The standard Oxford scale for fluorescein staining has the following criteria: Grade 0- Equal to or less than panel A; Grade I- Equal to or less than panel B, greater than panel A; Grade II- Equal to or less than panel C, greater than panel B; Grade III- Equal or less than panel D, greater than panel C; Grade IV- Equal or less than panel E, greater than panel D; Grade V- Greater than panel E.

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in lissamine green staining of the conjunctival surface
Tidsramme: Days: 0 (Basal Visit) and 8 (Final Visit)

Direct observation with slit lamp, graded according to (changes in ocular surface staining using the Sjögren's International Collaborative Clinical Alliance [SICCA].)

Days: 0 (Basal Visit) and 8 (Final Visit)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

30. juli 2027

Primær fullføring (Antatt)

30. mars 2028

Studiet fullført (Antatt)

30. april 2028

Datoer for studieregistrering

Først innsendt

12. april 2024

Først innsendt som oppfylte QC-kriteriene

16. april 2024

Først lagt ut (Faktiske)

19. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SOPH240-0923/I

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .